Sorafenib-induced acute interstitial pneumonia in patients with advanced hepatocellular carcinoma: Report of three cases

被引：14

作者：

Takeda H. ^{[1
]}

Nishikawa H. ^{[1
]}

Iguchi E. ^{[1
]}

Matsuda F. ^{[1
]}

Kita R. ^{[1
]}

Kimura T. ^{[1
]}

Osaki Y. ^{[1
]}

机构：

[1] Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Tennoji-ku, Osaka 543-8555

来源：

Clinical Journal of Gastroenterology | 2012年 / 5卷 / 6期

关键词：

Acute interstitial pneumonia; Adverse event; Hepatocellular carcinoma; Lung injury; Sorafenib;

D O I：

10.1007/s12328-012-0339-9

中图分类号：

学科分类号：

摘要：

Little is known about acute interstitial pneumonia (AIP) induced by sorafenib therapy in patients with advanced hepatocellular carcinoma (HCC). Here, we present three patients with advanced HCC who developed AIP during sorafenib therapy, with fatal complications in two cases. Case 1 was a 76-year-old man who developed dyspnea. Chest CT showed interstitial pneumonia. Sorafenib was discontinued immediately, and prednisolone was started. His pneumonia resolved. A drug-induced lymphocyte stimulation test for sorafenib was positive. Case 2 was a 75-year-old man and case 3 was a 77-year-old man, both of whom developed high-grade fever and hypoxemia during sorafenib therapy, and were diagnosed with AIP. In spite of high-dose steroid therapy, their respiratory failure worsened and both patients died. In all three cases, serum KL-6 or surfactant protein D concentrations were elevated, and blood and sputum cultures did not grow pathogens. All three patients were smokers with restrictive lung disease on preoperative respiratory function testing, but did not have respiratory symptoms before sorafenib therapy. The clinical features of these three cases suggest that male gender, older age, smoking history, and lung disease are associated with acute sorafenib-induced AIP in patients with advanced HCC. © 2012 Springer Japan.

引用

页码：407 / 412

页数：5

共 20 条

[1]

Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, pp. 378-390, (2008)

[2]

Abou-Alfa G.K., Schwartz L., Ricci S., Amadori D., Santoro A., Figer A., Et al., Phase II study of sorafenib in patients with advanced hepatocellular carcinoma, J Clin Oncol, 24, pp. 4293-4300, (2006)

[3]

Miyagawa N., Akaza H., Sorafenib (Nexavar), Gan to Kagaku Ryoho, 36, pp. 1029-1033, (2009)

[4]

Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., Et al., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial, Lancet Oncol, 10, pp. 25-34, (2009)

[5]

Nishikawa H., Osaki Y., Kita R., Kimura T., Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan, Cancer, 4, pp. 165-183, (2012)

[6]

Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Et al., BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res, 64, pp. 7099-7109, (2004)

[7]

Myung H.J., Jeong S.H., Kim J.W., Kim H.S., Jang J.H., Yoon H.I., Et al., Sorafenib-induced interstitial pneumonitis in a patient with hepatocellular carcinoma: A case report, Gut Liver., 4, pp. 543-546, (2010)

[8]

Ide S., Soda H., Hakariya T., Takemoto S., Ishimoto H., Tomari T., Et al., Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event, Lung Cancer., 67, pp. 248-250, (2010)

[9]

Safety Information for Nexabar™ 200 Mg Tablets, (2008)

[10]

Horiuchi-Yamamoto Y., Gemma A., Taniguchi H., Inoue Y., Sakai F., Et al., Drug-induced lung injury associated with sorafenib: Analysis of all-patient post-marketing surveillance in Japan, Int J Clin Oncol, (2012)

← 1 2 →